Основная статистика
| LEI | 5493002R27BBGV8DID60 |
| CIK | 706698 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Utah Medical Products, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 24, 2025 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) UTAH 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IR |
|
| July 24, 2025 |
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025 Contact: Brian Koopman (801) 566-1200July 24, 2025 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent with overall beginning-of-year projections. Currencies in this release are denoted as |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 001-12575 87-0342734 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive o |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS IN |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2025 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of (IRS Employer incorporati |
|
| April 29, 2025 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025 Contact: Brian Koopman (801) 566-1200April 29, 2025 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with its previously announced projections for calendar year 2025. Summary of results. The following is a s |
|
| April 29, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2025 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| April 4, 2025 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC (Ex |
|
| March 26, 2025 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 UTMD COMPENSATION CLAWBACK POLICY (Adopted November 1, 2024) 1.Purpose and Scope. Utah Medical Products, Inc. (the “Company”) has adopted this compensation clawback policy (the “Policy”) to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank”), as codified by Section 10D of the Securities Exchange Act of 1934 (the “Exchange Act |
|
| March 26, 2025 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21.1 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd.BermudaUtah Medical Products Ireland Columbia Medical & Surgical, Inc.OregonUtah Medical Products Abcorp MedicalFloridaUtah Medical Products Femcare Group LimitedUnited KingdomFemcare Group Femcare LimitedUnited KingdomFemcare Limited Femcare Australia Pty L |
|
| March 26, 2025 |
Exhibit 19.1 UTAH MEDICAL PRODUCTS, INC. STATEMENT OF POLICY REGARDING COMPLIANCE WITH FEDERAL SECURITIES LAWS July 25, 2003 THIS STATEMENT OF POLICY REGARDING COMPLIANCE WITH THE FEDERAL SECURITIES LAWS IS INTENDED TO FAMILIARIZE YOU WITH YOUR OBLIGATIONS AND RESPONSIBILITIES UNDER VARIOUS FEDERAL SECURITIES LAWS RELATING TO TRADING IN THE SECURITIES OF UTAH MEDICAL PRODUCTS, INC. IN THE INTEREST |
|
| March 26, 2025 |
SUMMARY of OFFICER and DIRECTOR COMPENSATION Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2025, the Company’s Chief Executive and Principal Financial Officer (the Company’s “Named Executive Officers”) are scheduled to receive the following comp |
|
| January 28, 2025 |
UTMD Reports Year 2024 and Fourth Quarter Financial Performance EXHIBIT 99.1 UTMD Reports Year 2024 and Fourth Quarter Financial Performance Contact: Brian Koopman (801) 566-1200January 28, 2025 Salt Lake City, Utah – With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (Nasdaq: UTMD) concluded a year of contraction. UTMD’s stock price declined 27%, more than twice the EPS decline, which |
|
| January 28, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 28, 2025 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCT |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2024 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| November 5, 2024 |
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend EXHIBIT 99.1 Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend Contact: Brian Koopman November 5, 2024 (801) 566-1200 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated wit |
|
| October 31, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Utah Medical Products Inc (Name of Issuer) Common Stock (Title of Class of Securities) 917488108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| October 29, 2024 |
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024 EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024 Contact: Brian Koopman (801) 566-1200October 29, 2024 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning |
|
| October 29, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 29, 2024 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH ME |
|
| July 25, 2024 |
Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 25, 2024 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IRS Employer inc |
|
| July 25, 2024 |
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024 Contact: Brian Koopman (801) 566-1200 July 25, 2024 Salt Lake City, Utah – As previously projected, Utah Medical Products, Inc. [Nasdaq: UTMD] realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 001-12575 87-0342734 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive o |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS IN |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 3, 2024 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of (IRS Employer incorporati |
|
| April 25, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2024 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| April 25, 2024 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024 Contact: Brian Koopman (801) 566-1200 April 25, 2024 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with its previously announced projections for calendar year 2024. Summary of results. The following is a |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 10, 2024 |
proxy statement SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| March 26, 2024 |
Summary of Officer and Director Compensation Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2024, the Company’s Chief Executive and Principal Financial Officer (the Company’s “Named Executive Officers”) are scheduled to receive the following comp |
|
| March 26, 2024 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Ireland Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Austral |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICA |
|
| January 30, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2024 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| January 30, 2024 |
UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance EXHIBIT 99.1 UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance Contact: Brian Koopman (801) 566-1200January 30, 2024 Salt Lake City, Utah – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management’s beginning of year projection |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCT |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 31, 2023 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| October 31, 2023 |
Utah Medical Products, Inc. Increases Regular Quarterly Dividend EXHIBIT 99.1 Utah Medical Products, Inc. Increases Regular Quarterly Dividend Contact: Brian Koopman October 31, 2023 (801) 566-1200 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business o |
|
| October 26, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 26, 2023 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| October 26, 2023 |
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023 EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023 Contact: Brian Koopman (801) 566-1200 October 26, 2023 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. Currenci |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH ME |
|
| July 25, 2023 |
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023 Contact: Brian Koopman (801) 566-1200 July 25, 2023 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections. Currencies in this release are de |
|
| July 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 25, 2023 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IRS Employer inc |
|
| July 14, 2023 |
Utah Medical Products, Inc., 2023 Employees’ and Directors’ Incentive Plan* proxy statement UTAH MEDICAL PRODUCTS, INC. 2023 EMPLOYEES’ AND DIRECTORS’ NON-STATUTORY STOCK OPTION AND STOCK PURCHASE RIGHTS PLAN Utah Medical Products, Inc., a Utah corporation (the “Company”), hereby adopts this “2023 Employees’ and Directors’ Non-statutory Stock Option and Stock Purchase Rights Plan” (the “Plan”). 1.Purpose of the Plan. The Board has adopted this Plan with the intent, and di |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 87-0342734 (State or jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 7043 South 300 West, Midvale, Utah 84047 (Address of Principal Executi |
|
| July 14, 2023 |
Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) UTAH MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity(1) Common Stock Other |
|
| May 30, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87-0342734 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal |
|
| May 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2023 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation or org |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS IN |
|
| April 25, 2023 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023 Contact: Brian Koopman (801) 566-1200April 25, 2023 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2023, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals previously announced for calendar year 2023. Summary of results. The following is |
|
| April 25, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2023 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 4, 2023 |
proxy statement SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| March 28, 2023 |
Summary of Officer and Director Compensation Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2023, the Company’s Chief Executive and Principal Financial Officer (the Company’s “Named Executive Officers”) are scheduled to receive the following comp |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001 |
|
| March 28, 2023 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Australia Pty L |
|
| March 27, 2023 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Australia Pty L |
|
| March 27, 2023 |
Summary of Officer and Director Compensation Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2023, the Company’s Chief Executive and Principal Financial Officer (the Company’s “Named Executive Officers”) are scheduled to receive the following comp |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICA |
|
| February 14, 2023 |
UTMD / Utah Medical Products, Inc. / T. Rowe Price Investment Management, Inc. Passive Investment SC 13G 1 utmd13gdec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) UTAH MEDICAL PRODUCTS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917488108 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule p |
|
| February 9, 2023 |
UTMD / Utah Medical Products, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02153-utahmedicalproductsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Utah Medical Products Inc. Title of Class of Securities: Common Stock CUSIP Number: 917488108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| January 31, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 31, 2023 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| January 31, 2023 |
UTMD Reports Audited Year 2022 and Fourth Quarter Financial Performance EXHIBIT 99.1 UTMD Reports Audited Year 2022 and Fourth Quarter Financial Performance Contact: Brian Koopman (801) 566-1200January 31, 2023 Salt Lake City, Utah – Utah Medical Products, Inc. (Nasdaq: UTMD) finished the calendar year with a solid fourth quarter (4Q) performance, which allowed financial results for the year 2022 exceeding management’s beginning of year projections, despite many chall |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCT |
|
| November 1, 2022 |
Utah Medical Products, Inc. Increases Regular Quarterly Dividend EXHIBIT 99.1 Utah Medical Products, Inc. Increases Regular Quarterly Dividend Contact: Crystal RiosNovember 1, 2022 (801) 566-1200 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($.295) per share of common stock payable on January 4, 2023 to shareholders of record at the cl |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2022 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| October 25, 2022 |
Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 25, 2022 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IRS Employer |
|
| October 25, 2022 |
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022 EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022 Contact: Crystal Rios (801) 566-1200 October 25, 2022 Salt Lake City, Utah ? In the third calendar quarter (3Q) of 2022, despite significant cost inflation, supply chain disruption, litigation expenses and negative impact of a stronger U.S. Dollar on foreign currency sales, Utah Medical Products, Inc. ( |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH ME |
|
| July 28, 2022 |
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022 Contact: Crystal Rios (801) 566-1200 July 26, 2022 Salt Lake City, Utah ? UTMD achieved second calendar quarter (2Q) and first half (1H) 2022 financial results better than those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Aus |
|
| July 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2022 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IR |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87-0342734 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 7043 South 300 West Midvale, Utah 84047 (Address of principal executive of |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS IN |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2022 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of (I.R.S. Employer incorpor |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 26, 2022 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| April 27, 2022 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2022 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2022 Contact: Crystal Rios (801) 566-1200 April 26, 2022 Salt Lake City, Utah ? In the first calendar quarter (1Q) of 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals for calendar year 2022. Summary of results. The following is a summary comparison |
|
| April 13, 2022 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICA |
|
| March 25, 2022 |
Summary of Officer and Director Compensation Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2022, the Company?s Chief Executive and Principal Financial Officer (the Company?s ?Named Executive Officers?) are scheduled to receive the following comp |
|
| March 25, 2022 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Australia Pty L |
|
| February 10, 2022 |
UTMD / Utah Medical Products, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Utah Medical Products Inc. Title of Class of Securities: Common Stock CUSIP Number: 917488108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 8, 2022 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| February 8, 2022 |
Utah Medical Products, Inc. Announces Quarterly Dividend EXHIBIT 99.1 Utah Medical Products, Inc. Announces Quarterly Dividend Contact: Crystal RiosFebruary 8, 2022 (801) 566-1200 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine cents ($.29) per share of common stock payable on April 5, 2022 to shareholders of record at the close of business on March |
|
| February 2, 2022 |
UTMD Reports Audited Year 2021 and Fourth Quarter Financial Performance EXHIBIT 99.1 UTMD Reports Audited Year 2021 and Fourth Quarter Financial Performance Contact: Crystal Rios (801) 566-1200 February 1, 2022 Salt Lake City, Utah ? The fourth calendar quarter (4Q) of 2021 financial results demonstrate Utah Medical Products, Inc.?s (Nasdaq: UTMD?s) continuing performance improvement despite many challenges related to the corona virus pandemic including on-again/off-a |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 1, 2022 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCT |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2021 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| November 2, 2021 |
Utah Medical Products, Inc. Announces Special Dividend EXHIBIT 99.1 Utah Medical Products, Inc. Announces Special Dividend Contact: Crystal Rios November 2, 2021 (801) 566-1200 Salt Lake City, Utah -Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a special cash dividend of two dollars ($2.00) per share of common stock payable on December 29, 2021 to stockholders of record at the close of business on December 1 |
|
| October 26, 2021 |
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2021 EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2021 Contact: Crystal Rios (801) 566-1200 October 26, 2021 Salt Lake City, Utah ? The third calendar quarter (3Q) of 2021 financial results continued to demonstrate Utah Medical Products, Inc.?s (Nasdaq: UTMD?s) recovery after a time when there were restrictions on so-called nonessential medical procedures d |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 26, 2021 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH ME |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 22, 2021 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IR |
|
| July 22, 2021 |
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2021 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2021 Contact: Crystal Rios (801) 566-1200July 22, 2021 Salt Lake City, Utah ? The second calendar quarter (2Q) of 2021 financial results were dramatically different from 2Q 2020 because 2Q 2020 results were the low point of Utah Medical Products, Inc.?s (Nasdaq: UTMD) performance during the COVID-19 pandemic |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87-0342734 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive off |
|
| May 11, 2021 |
Quarterly Report - UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS IN |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2021 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UT 87-0342734 (State or other jurisdiction of incorporation or organizati |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 22, 2021 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| April 23, 2021 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2021 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2021 Contact: Crystal Rios (801) 566-1200April 22, 2021 Salt Lake City, Utah ? Because of the aberration in results which began in March 2020 due to the impact of restrictions on ?nonessential? medical procedures, Utah Medical Products, Inc. (Nasdaq: UTMD) will report 2021 quarterly income statement results co |
|
| April 12, 2021 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| March 26, 2021 |
Annual Report - UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICA |
|
| March 26, 2021 |
Summary of Officer and Director Compensation Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2021, the Company?s Chief Executive and Principal Financial Officer (the Company?s ?Named Executive Officers?) are scheduled to receive the following comp |
|
| March 26, 2021 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Australia Pty L |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 1, 2021 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IR |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Utah Medical Products Inc. Title of Class of Securities: Common Stock CUSIP Number: 917488108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 28, 2021 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| January 28, 2021 |
UTMD Reports Audited Year 2020 and Fourth Quarter Financial Performance EXHIBIT 99.1 UTMD Reports Audited Year 2020 and Fourth Quarter Financial Performance Contact: Crystal Rios (801) 566-1200January 28, 2021 Salt Lake City, Utah –Utah Medical Products, Inc. (Nasdaq: UTMD) reports financial results for the fourth calendar quarter (4Q) which confirms a trend of recovery from the “COVID-19 depression” in 2Q 2020 caused by government policies restricting medical procedu |
|
| November 9, 2020 |
Quarterly Report - UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UT |
|
| November 6, 2020 |
Quarterly Report - UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCT |
|
| November 3, 2020 |
- UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2020 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| November 3, 2020 |
Utah Medical Products, Inc. Increases Quarterly Dividend EXHIBIT 99.1 Utah Medical Products, Inc. Increases Quarterly Dividend Contact: Crystal RiosNovember 3, 2020 (801) 566-1200 Salt Lake City, Utah -Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-eight and one-half cents ($.285) per share of common stock payable on January 5, 2021 to shareholders of record at the close of b |
|
| October 27, 2020 |
- UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 27, 2020 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| October 27, 2020 |
UTMD Reports Financial Performance for Third Quarter and Nine Months of Year 2020 EXHIBIT 99.1 UTMD Reports Financial Performance for Third Quarter and Nine Months of Year 2020 Contact: Crystal Rios (801) 566-1200October 27, 2020 Salt Lake City, Utah – For the third calendar quarter (3Q) and first nine months (9M) of 2020, Utah Medical Products, Inc. (Nasdaq: UTMD) reports financial results described by CEO Kevin Cornwell as follows, “As stockholders know, the desire to preserv |
|
| August 10, 2020 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2020 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of (I.R.S. |
|
| August 7, 2020 |
Quarterly Report - UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH ME |
|
| July 28, 2020 |
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2020 EX-99.1 2 utahex99z1.htm FINANCIAL INFORMATION EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2020 Contact: Crystal Rios (801) 566-1200July 28, 2020 Salt Lake City, Utah – As many of the gynecology devices provided by Utah Medical Products, Inc. (Nasdaq: UTMD) are used in “nonessential” or “elective” procedures, as medical procedures have been reclassifi |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 28, 2020 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (IR |
|
| July 14, 2020 |
proxy statement SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| May 29, 2020 |
- UTAH MEDICAL PRODUCTS INC - FORM SD UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 1-12575 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal |
|
| May 8, 2020 |
Exhibit 4 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian L. Koopman, Principal Financial Offi |
|
| May 8, 2020 |
Exhibit 3 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin L. Cornwell, Chief Executive Officer |
|
| May 8, 2020 |
EX-2 3 utmdex2.htm CERTIFICATION Exhibit 2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Brian L. Koopman, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| May 8, 2020 |
Quarterly Report - UTAH MEDICAL 10-Q UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDIC |
|
| May 8, 2020 |
Exhibit 1 CERTIFICATION OF CEO PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin L. |
|
| April 23, 2020 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2020 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2020 Contact: Crystal Rios (801) 566-1200April 23, 2020 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2020, Utah Medical Products, Inc. (Nasdaq: UTMD) attained results consistent with 1Q 2019, despite realizing a negative impact from the public response to the corona virus (COVID-19). Summary of |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 23, 2020 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| March 31, 2020 |
UTMD / Utah Medical Products, Inc. 10-K/A - Annual Report - 10KA1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K/ A (Amendment No. 1) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MED |
|
| March 24, 2020 |
UTMD Postpones its 2020 Annual Stockholders’ Meeting for Three Months EX-99.1 2 exh991.htm UTMD POSTPONES ITS 2020 ANNUAL STOCKHOLDERS' MEETING FOR THREE MONTHS EXHIBIT 99.1 UTMD Postpones its 2020 Annual Stockholders’ Meeting for Three Months Contact: Crystal Rios March 23, 2020 (801) 566-1200 Salt Lake City, Utah – As stockholders of Utah Medical Products, Inc. (Nasdaq: UTMD) appreciate, as a result of the recent rapid spread of the COVID-19 (corona virus), the wa |
|
| March 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 23, 2020 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) (I |
|
| March 16, 2020 |
SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Exhibit 21 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Australia Pty L |
|
| March 16, 2020 |
Summary of Officer and Director Compensation Exhibit 10.6 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2020, the Company’s Chief Executive and Principal Financial Officer (the Company’s “Named Executive Officers”) are scheduled to receive the following comp |
|
| March 16, 2020 |
UTMD / Utah Medical Products, Inc. 10-K - Annual Report - 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC (Ex |
|
| January 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2020 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| January 30, 2020 |
UTMD Reports Audited Year 2019 and Fourth Quarter Financial Performance EX-99.1 2 exh991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2019 AND FORWARD-LOOKING STATEMENTS RELATING TO 2019 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JANUARY 30, 2020. EXHIBIT 99.1 UTMD Reports Audited Year 2019 and Fourth Quarter Financial Performance Contact: Crystal Rios January 30, 2020 (801) 566-1200 Salt Lake City, |
|
| November 7, 2019 |
UTMD / Utah Medical Products, Inc. 10-Q - Quarterly Report - 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-12575 UTAH MEDICAL PRODUCTS |
|
| November 5, 2019 |
EXHIBIT 99.1 Salt Lake City, Utah ‑Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-eight cents ($.28) per share of common stock payable on January 3, 2020 to shareholders of record at the close of business on December 13, 2019. This is a 2% increase over the prior quarterly cash dividend. Utah Medical Products, Inc., wit |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 5, 2019 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organiza |
|
| October 24, 2019 |
UTMD Reports Financial Performance for Third Quarter and Nine Months of Year 2019 EXHIBIT 99.1 UTMD Reports Financial Performance for Third Quarter and Nine Months of Year 2019 Contact: Crystal Rios (801) 566-1200 October 24, 2019 Salt Lake City, Utah – In the third calendar quarter (3Q) and first nine months (9M) of 2019, Utah Medical Products, Inc. (Nasdaq: UTMD) attained results which reflect that the Company is likely to exceed its overall revenue growth goal, but fall some |
|
| October 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 24, 2019 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organiza |
|
| September 10, 2019 |
UTMD / Utah Medical Products, Inc. CORRESP - - 11 September 2019 Gary Newberry Division of Corporation Finance U.S. Securities and Exchange Commission Washington D.C. 20549-0306 VIA FACSIMILE [703-813-6985] and U.S. Certified Mail Re: Utah Medical Products, Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed March 31, 2019 Form 10-Q for the Fiscal Quarter Ended June 30, 2019 Filed August 9, 2019 File No. 001-12575 Dear Mr. Newberr |
|
| August 9, 2019 |
UTMD / Utah Medical Products, Inc. 10-Q - Quarterly Report - 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC |
|
| July 30, 2019 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2019 EX-99.1 2 exh991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND FORWARD-LOOKING STATEMENTS RELATING TO 2019 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JULY 30, 2019. EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2019 Contact: Crystal Rios (801) 566-1200 July 30, 2019 Salt Lake City, Ut |
|
| July 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2019 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organizatio |
|
| June 7, 2019 |
UTMD / Utah Medical Products, Inc. / LAZARD ASSET MANAGEMENT LLC Passive Investment r13gaadvanceautoparts SCHEDULE 13G/A CUSIP No: 917488108 1)NAME OF REPORTING PERSON S. |
|
| May 31, 2019 |
UTMD / Utah Medical Products, Inc. SD - - FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87‑0342734 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive off |
|
| May 9, 2019 |
UTMD / Utah Medical Products, Inc. 10-Q Quarterly Report 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: March 31, 2019 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| May 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 3, 2019 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organiza |
|
| April 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2019 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organizati |
|
| April 25, 2019 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2019 EX-99.1 2 exh991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND FORWARD-LOOKING STATEMENTS RELATING TO 2019 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED APRIL 25, 2019. EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2019 Contact: Crystal Rios (801) 566-1200 April 25, 2019 Salt Lake City, Utah – I |
|
| April 4, 2019 |
UTMD / Utah Medical Products, Inc. DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Under Rule 14a-12 Utah Medical Products, Inc. |
|
| March 14, 2019 |
Summary of Officer and Director Compensation EX-10.5 2 exh105.htm SUMMARY OF OFFICER AND DIRECTOR COMPENSATION Exhibit 10.5 SUMMARY of OFFICER and DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its Directors and Executive Officers. During 2019, the Company’s Chief Executive and Principal Financial Officer (the Company’s “Name |
|
| March 14, 2019 |
UTMD / Utah Medical Products, Inc. 10K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission File Number: 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| March 14, 2019 |
Subsidiaries of Utah Medical Products, Inc. Exhibit 21.1 SUBSIDIARIES of UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Limited United Kingdom Femcare Limited Femcare Australia Pty |
|
| February 13, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or l5(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 1, 2019 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| February 13, 2019 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| February 13, 2019 |
begin 644 exh101.pdf M)5!$1BTQ+C8-)>+CS],-"C$W,R P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O M9&4O1FERR@AS,.TH';BW-W9U!SW] M(?GZ)12U! FH$;8[#@6H$LX-8)IQ)J!0 HN1W3O?MP,%= ^8+;829*"BN^-R&Q\<^VYRM&[7ZW85@=I;-W]] M*48?!B;Y]YVM>YB!/\%TSHSWVL^?:]X"# "OZ5K6#0IE;F1S=')E86T-96YD M;V)J#3$W-" P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O1FER') '5%S7-2!1X!Z A@P8!V@Q M0*T!/8^R/$(1@N4AQ(.< 3(\R+-I:]A6-*4=! U::6*C"C3IP!4/VE@VPU:T |
|
| February 12, 2019 |
UTMD / Utah Medical Products, Inc. / LAZARD ASSET MANAGEMENT LLC Passive Investment r13gaadvanceautoparts SCHEDULE 13G CUSIP No: 917488108 1)NAME OF REPORTING PERSON S. |
|
| January 31, 2019 |
UTMD Reports Audited Year 2018 and Fourth Quarter Financial Performance Exhibit 99.1 UTMD Reports Audited Year 2018 and Fourth Quarter Financial Performance Contact: Crystal Rios January 31, 2019 (801) 566-1200 Salt Lake City, Utah – Excluding a large favorable adjustment correcting the U.S. repatriation tax (REPAT) on foreign subsidiary cash and cumulative earnings (E&P), Utah Medical Products, Inc. (Nasdaq: UTMD) concluded a solid year in 2018 in which it was able t |
|
| January 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 31, 2019 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of (Commission File Number) |
|
| January 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 31, 2018 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| November 16, 2018 |
Exhibit 16.1 |
|
| November 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 13, 2018 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| November 7, 2018 |
UTMD / Utah Medical Products, Inc. 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: September 30, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organization) (I.R.S |
|
| October 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2018 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organiza |
|
| October 30, 2018 |
EXHIBIT 99.1 Salt Lake City, Utah ‑Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-seven and one-half cents ($.275) per share of common stock payable on January 3, 2019 to shareholders of record at the close of business on December 14, 2018. This is a 2% increase over the prior quarterly cash dividend. Utah Medical Produ |
|
| October 23, 2018 |
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2018 EX-99.1 2 991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND FORWARD-LOOKING STATEMENTS RELATING TO 2018 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED OCTOBER 23, 2018. Exhibit 99.1 Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2018 Contact: Crystal Rios (801) 566-1200 October 23, 2018 Salt Lake |
|
| October 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 23, 2018 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organiza |
|
| October 18, 2018 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2018 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2018 Contact: Crystal Rios (801) 566-1200 July 24, 2018 Salt Lake City, Utah – In the second calendar quarter (2Q) and first half (1H) of 2018, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved results which reflect that the Company remains on target to achieve beginning of year goals for 2018. Currencies i |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 24, 2018 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 000-12575 87-0342734 (State or other jurisdiction of incorporation or organizatio |
|
| August 9, 2018 |
UTMD / Utah Medical Products, Inc. 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: June 30, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| May 31, 2018 |
UTMD / Utah Medical Products, Inc. FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87‑0342734 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive off |
|
| May 9, 2018 |
UTMD / Utah Medical Products, Inc. 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: March 31, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| May 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 4, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organiza |
|
| April 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 26, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organ |
|
| April 26, 2018 |
Exhibit 99.1 UTAH MEDICAL PRODUCTS, INC. 7043 South 300 West Midvale, Utah 84047 Telephone: 801-566-1200 FAX: 801-566-2062 Nasdaq Symbol: UTMD www.utahmed.com PRESS RELEASE Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2018 Contact: Crystal Rios (801) 566-1200 April 26, 2018 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2018, Utah Medical Products, Inc. |
|
| April 9, 2018 |
UTMD / Utah Medical Products, Inc. PX14A6G April 9, 2018 Dear Utah Medical Products, Inc. Shareowner: Support Shareowner Proposal #4 Requesting Majority Vote We urge shareowners to support Proposal #4 at the Utah Medical Products, Inc. May 4, 2018 Annual General Meeting. As of record date March 2, 2018, CalPERS owned approximately 16,500 shares of Utah Medical Products, Inc. common stock. As a long-term shareowner of the company we ask tha |
|
| April 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 2, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organi |
|
| March 8, 2018 |
UTMD / Utah Medical Products, Inc. DEF14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 6, 2018 |
SUMMARY OF OFFICER AND DIRECTOR COMPENSATION Exhibit 10.5 EXHIBIT 11 SUMMARY OF OFFICER AND DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its directors and Executive Officers. During 2018, the Company's Chief Executive and Principal Financial Officers (the Company's "Named Executive Officers") are scheduled to receive the fo |
|
| March 6, 2018 |
UTMD / Utah Medical Products, Inc. 10K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Commission File Number: 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| March 6, 2018 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 21 EXHIBIT 12 SUBSIDIARIES OF UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Holdings Limited United Kingdom n/a – not a trading |
|
| January 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2018 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| January 30, 2018 |
UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2017 EXHIBIT 99.1 UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2017 Contact: Paul Richins January 30, 2018 (801) 566-1200 Salt Lake City, Utah ? Utah Medical Products, Inc. (Nasdaq: UTMD) concluded an outstanding year in 2017 in which it harvested distribution changes that had been in the making for several years. Although UTMD substantially exceeded management expectations fo |
|
| November 7, 2017 |
UTMD / Utah Medical Products, Inc. 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: September 30, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organization) (I.R.S |
|
| October 31, 2017 |
EXHIBIT 99.1 Salt Lake City, Utah ?Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-seven cents ($.27) per share of common stock payable on January 3, 2018 to shareholders of record at the close of business on December 15, 2017. This is a 2% increase over the prior quarterly cash dividend. Utah Medical Products, Inc., wit |
|
| October 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 31, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| October 24, 2017 |
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2017 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2017 Contact: Paul Richins October 24, 2017 (801) 566-1200 Salt Lake City, Utah ? In the third calendar quarter (3Q) and first nine months (9M) of 2017, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved results which confirm that the Company is very likely to significantly exceed its previously announced goa |
|
| October 24, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 24, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| August 3, 2017 |
UTMD / Utah Medical Products, Inc. 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: June 30, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| July 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 25, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organi |
|
| July 25, 2017 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2017 EX-99.1 2 exh991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND FORWARD-LOOKING STATEMENTS RELATING TO 2017 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JULY 25, 2017. EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2017 Contact: Paul Richins July 25, 2017 (801) 566-1200 Salt Lake City, Ut |
|
| May 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87?0342734 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive off |
|
| May 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organiza |
|
| May 5, 2017 |
Utah Medical Products 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: March 31, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| April 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organ |
|
| April 25, 2017 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2017 EX-99.1 2 exh991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND FORWARD-LOOKING STATEMENTS RELATING TO 2017 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED APRIL 25, 2017. Exhibit 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2017 Contact: Paul Richins April 25, 2017 (801) 566-1200 Salt Lake City, Utah – I |
|
| March 10, 2017 |
Utah Medical Products UTAH MEDICAL PROXY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 8, 2017 |
Utah Medical Products 10K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission File Number: 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| March 8, 2017 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 10.5 EXHIBIT 11 SUMMARY OF OFFICER AND DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its directors and Executive Officers. During 2017, the Company's Chief Executive and Principal Financial Officers (the Company's "Named Executive Officers") are scheduled to receive the fo |
|
| March 8, 2017 |
Exhibit 21.1 EXHIBIT 12 SUBSIDIARIES OF UTAH MEDICAL PRODUCTS, INC. Subsidiary Name Jurisdiction of Organization Business Name Utah Medical Products Ltd. Bermuda Utah Medical Products Columbia Medical & Surgical, Inc. Oregon Utah Medical Products Abcorp Medical Florida Utah Medical Products Femcare Group Limited United Kingdom Femcare Group Femcare Holdings Limited United Kingdom n/a – not a tradi |
|
| February 10, 2017 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* UTAH MEDICAL PRODUCTS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917488108 (CUSIP Number) DECEMBER 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 31, 2017 |
UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2016 Exhibit 99.1 UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2016 Contact: Paul Richins January 31, 2017 (801) 566-1200 Salt Lake City, Utah – Utah Medical Products, Inc. (Nasdaq: UTMD) concluded a year in 2016 in which Operating Income (OI) and Earnings Per Share (EPS) per U.S. Generally Accepted Accounting Principles (US GAAP) were up 3% despite weak demand from its larges |
|
| January 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 31, 2017 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| November 4, 2016 |
Utah Medical Products 10Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: September 30, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organization) (I.R.S |
|
| November 1, 2016 |
EX-99.1 2 exhibit991.htm PRESS RELEASE EXHIBIT 99.1 Salt Lake City, Utah ‑Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-six and one half cents ($.265) per share of common stock payable on December 30, 2016 to shareholders of record at the close of business on December 16, 2016. This is a 2% increase over the prior quar |
|
| November 1, 2016 |
Utah Medical Products FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| October 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 25, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| October 25, 2016 |
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2016 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2016 Contact: Paul Richins October 25, 2016 (801) 566-1200 Salt Lake City, Utah ? In the third calendar quarter (3Q) and first nine months (9M) of 2016, Utah Medical Products, Inc.'s (Nasdaq: UTMD) changes in income statement results compared to the same time periods in the prior calendar year were as follows: |
|
| August 8, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 10Q 2016-06-29 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: June 30, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| July 26, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organi |
|
| July 26, 2016 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2016 EX-99.1 2 exh991.htm FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND FORWARD-LOOKING STATEMENTS RELATING TO 2016 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JULY 26, 2016. EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2016 Contact: Paul Richins July 26, 2016 (801) 566-1200 Salt Lake City, Ut |
|
| July 26, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organi |
|
| July 26, 2016 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2016 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2016 Contact: Paul Richins July 26, 2016 (801) 566-1200 Salt Lake City, Utah ? In the second calendar quarter (2Q) and first half (1H) of 2016, Utah Medical Products, Inc. (Nasdaq: UTMD) continued to achieve results which are on track to meet its previously announced goals for 2016. Currencies in this report |
|
| July 26, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87‑0342734 (State or other jurisdiction of incorporation or organi |
|
| July 26, 2016 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2016 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2016 Contact: Paul Richins July 26, 2016 (801) 566-1200 Salt Lake City, Utah ? In the second calendar quarter (2Q) and first half (1H) of 2016, Utah Medical Products, Inc. (Nasdaq: UTMD) continued to achieve results which are on track to meet its previously announced goals for 2016. Currencies in this report |
|
| May 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 1-12575 87?0342734 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive off |
|
| May 6, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 10Q 2016-03-31 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: March 31, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| May 2, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2016-04-29 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organ |
|
| April 26, 2016 |
Utah Medical Products FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 26, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organ |
|
| April 26, 2016 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2016 Exhibit 99.1 EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2016 Contact: Paul Richins April 26, 2016 (801) 566-1200 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2016, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved results representing a solid start to meeting its previously announced goals for 2016. Summary of results. The following i |
|
| March 10, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 10K 2015-12-31 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Commission File Number: 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| March 10, 2016 |
Utah Medical Products UTAH MEDICAL PROXY March 5, 2016 Dear UTMD Shareholder: You are cordially invited to attend the 2016 Annual Meeting of Shareholders of Utah Medical Products, Inc. |
|
| March 10, 2016 |
SUMMARY OF OFFICER AND DIRECTOR COMPENSATION Exhibit 10.5 SUMMARY OF OFFICER AND DIRECTOR COMPENSATION The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its directors and Executive Officers. During 2016, the Company's Chief Executive and Principal Financial Officers (the Company's "Named Executive Officers") are scheduled to receive the following com |
|
| February 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Utah Medical Products, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917488108 (CUSIP Number) 12/31/2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 11, 2016 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* UTAH MEDICAL PRODUCTS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917488108 (CUSIP Number) DECEMBER 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) UTAH MEDICAL PRODUCTS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917488108 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sch |
|
| February 2, 2016 |
UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2015 Exhibit 99.1 UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2015 Contact: Paul Richins February 2, 2016 (801) 566-1200 Salt Lake City, Utah ? Utah Medical Products, Inc. (Nasdaq: UTMD) concluded a financial year in 2015 dominated by changes in foreign currency exchange (FX) rates. Despite a weak fourth calendar quarter (4Q) due to international distributor order patterns, r |
|
| February 2, 2016 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2016-02-02 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 2, 2016 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or org |
|
| December 16, 2015 |
December 16, 2015 Kevin Kuhar, Accounting Branch Chief Office of Electronics and Machinery Division of Corporation Finance U. |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: September 30, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87?0342734 (State or other jurisdiction of incorporation or organization) (I.R.S |
|
| November 3, 2015 |
EXHIBIT 99.1 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-six cents ($.26) per share of common stock payable on December 30, 2015 to shareholders of record at the close of business on December 16, 2015. This is a 2% percent increase over the prior quarterly cash dividend. Utah Medical Products, |
|
| November 3, 2015 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2015-11-03 (Current Report/Significant Event) utah.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorporati |
|
| October 22, 2015 |
Utah Medical Products FORM 8-K (Current Report/Significant Event) utmed8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 22, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorpo |
|
| October 22, 2015 |
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2015 exhibit99-1.htm Exhibit 99.1 Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2015 Contact: Paul Richins October 22, 2015 (801) 566-1200 Salt Lake City, Utah ? In the third calendar quarter (3Q) and first nine months (9M) of 2015, Utah Medical Products, Inc.?s (Nasdaq: UTMD) changes in income statement results compared to the same time periods in the prior calendar year |
|
| August 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: June 30, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| July 23, 2015 |
Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2015 utahexh991.htm EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2015 Contact: Paul Richins July 23, 2015 (801) 566-1200 Salt Lake City, Utah ? In the second calendar quarter (2Q) and first half (1H) of 2015, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved results which are on track to meet its previously announced goals for 2015, despite greater than ex |
|
| July 23, 2015 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2015-07-23 (Current Report/Significant Event) utah.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 23, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorporation |
|
| June 1, 2015 |
Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: March 31, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| May 6, 2015 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 10 Exhibit 1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (?Amendment? is dated as of November 18, 2014 (the ?Effective Date?) by and between Utah Medical Products, Inc. |
|
| May 4, 2015 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2015-05-01 (Current Report/Significant Event) utah.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 1, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorporation or |
|
| April 23, 2015 |
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2015 utahmedexh991.htm EXHIBIT 99.1 Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2015 Contact: Paul Richins April 23, 2015 (801) 566-1200 Salt Lake City, Utah – In the first calendar quarter (1Q) of 2015, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved results representing a solid start to meeting its previously announced goals for 2015, despite significant foreign cu |
|
| April 23, 2015 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. 8K 2015-04-23 (Current Report/Significant Event) utahmed.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 23, 2015 Commission File No. 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorporat |
|
| March 12, 2015 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| March 12, 2015 |
Utah Medical Products UTAH MEDICAL PRODUCTS, INC. DEF 14A 2015-03-10 DEF 14A 1 utahmed.htm UTAH MEDICAL PRODUCTS, INC. DEF 14A 2015-03-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commis |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Commission File Number: 001-12575 UTAH MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) Utah 87-0342734 (State or other jurisdiction of incorporation or organiz |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Utah Medical Products, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917488108 (CUSIP Number) 12/31/2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2015 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* UTAH MEDICAL PRODUCTS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917488108 (CUSIP Number) DECEMBER 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) UTAH MEDICAL PRODUCTS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917488108 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sch |
